News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
XOMA Reports Third Quarter 2004 Financial Results; RAPTIVA Approved In More Than 30 Countries, Including European Union
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
XOMA Ltd. (Nasdaq:XOMA), a biopharmaceutical development company, announced results for the quarter ended September 30, 2004.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
March 9, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
Vertex Terminates 20 in Reorganization Push
March 9, 2026
·
32 min read
·
BioSpace Editorial Staff
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
March 6, 2026
·
1 min read
·
Annalee Armstrong
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
·
2 min read
·
Heather McKenzie
